With the number of end-stage renal disease (ESRD) patients growing, one of the crucial questions facing health care professionals and funding agencies in Asia is whether funding for dialysis will be sufficient to keep up with demand.
During the ISPD's 2006 Congress, academic nephrologists and government officials from China, Hong Kong, India, Indonesia, Japan, Macau, Malaysia, Philippines, Singapore, Taiwan, Thailand, and Vietnam participated in a roundtable discussion on dialysis economics in Asia. The focus was policy and health care financing. The roundtable addressed ESRD growth in Asia and how to obtain enough funding to keep up with the growth in patient numbers. Various models were presented: the “peritoneal dialysis (PD) first” policy model, incentive programs, nongovernmental organizations providing PD, and PD reimbursement in a developing economy. This article summarizes the views of the participant nephrologists on how to increase the utilization of PD to improve on clinical and financial management of patients with ESRD.
LysaghtMJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol2002; 13(Suppl 1):S37–40.
2.
LiPKWeeningJJDirksJLuiSLSzetoCCTangS., Participants of ISN Consensus Workshop on Prevention of Progression of Renal Disease. A report with consensus statements of the International Society of Nephrology 2004 Consensus Workshop on Prevention of Progression of Renal Disease, Hong Kong, June 29, 2004. Kidney Int2005; (Suppl 94):S2–7
3.
LeeG.End-stage renal disease in the Asian–Pacific region. Semin Nephrol2003; 23:107–14.
4.
WuAYKongNCde LeonFAPanCYTaiT YYeungVT. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia2005; 48:17–26.
5.
De VecchiAFDratwaMWiedemannME. Healthcare systems and end-stage renal disease (ESRD) therapies—an international review: costs and reimbursement/funding of ESRD therapies. Nephrol Dial Transplant1999; 14(Suppl 6):31–41.
6.
HoYWChauKFLeungCBChoyBYTsangWKWongPN. Hong Kong Renal Registry Report 2004. Hong Kong J Nephrol2005; 7:38–46.
7.
LiPKTChowKM. The cost barrier to peritoneal dialysis in the developing world—an Asian perspective. Perit Dial Int2001; 21(Suppl 3):S307–13.
8.
BlakePG. Peritoneal dialysis in Asia: an external perspective. Perit Dial Int2002; 22:258–64.
9.
MoradZLeeDGLimYNTanPC. Peritoneal dialysis in Malaysia. Perit Dial Int2005; 25:426–31.
10.
TanCChanCMHoCKWongKSLeeEJWooK T. Health economics of renal replacement therapy: perspectives from Singapore. Kidney Int2005; 67(Suppl 94):S19–22.
11.
VoneshEFSnyderJJFoleyRNCollinsAJ. Mortality studies comparing peritoneal dialysis and hemodialysis: what do they tell us?Kidney Int2006; 70(Suppl 103):S3–11.
12.
LiPKTChowKMSzetoCC. Is there a survival advantage in Asian peritoneal dialysis patients?Int J Artif Organs2003; 26:363–72.
13.
NaitoH.The Japanese health-care system and reimbursement for dialysis. Perit Dial Int2006; 26:155–61.
